RVNC - Earnings call transcript Q2 2021 | Revance Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, everyone. Welcome to Revance Therapeutics Second Quarter 2021 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, August 5, 2021. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance please go ahead, ma’am.

Jessica Serra

Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Tobin Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Officer, and Therapeutics, Technology, Commercial President Sjuts; Chief Innovation of Aubrey Joshi; Aesthetics Dustin and and Abhay Rankin.

product clinical During make this potential technology, of benefits the candidates drug commercialization the forward-looking will business our development and statements including of guidance, planned conference are statements related plans, performance. the call, approval current operations, inherently candidates, our management launch of product strategy, our on to injection, XXXX the These company's potential DaxibotulinumtoxinA financial and statements any next-generation expected timing fintech expectations runway of involve based and platform, the significant forward-looking cash uncertainties. for and risks of

risks Our our turn will A those actual such measures a reconciliation and forward-looking both of events and these on included to GAAP in timing as GAAP With measures. the I anticipated call uncertainties. Mark? call, today's release. could and differ Foley. present non-GAAP Also we in of the materially financial will Mark statements to that, from of earnings over non-GAAP results result

Mark Foley

you, thank rate. joining XXXX $XXX highlighted And services, million quarter $XX results second call. second processing RHA you results in over over X,XXX run strong volume shared Good revenue accounts across Jessica. million products conference report our very financial afternoon, We're by for quarter aesthetic and pleased Thank to everyone. and in fintech

the and on since to aesthetics healthy exceptional have by quarter by strategy. and commercial commitment to to a continue growth not working by results led to launch the supported able and their team. revenue deliver impressed company a unwavering to been our without we've would organization I objectives. been execution, entire Revance market attract further talent our on our focus the together becoming These as dedication commercial Our be of entity possible consecutive validated third

our injection for lead manufacturing of building is for In the actively June, meantime, solidifying year. team anticipate in to for glabellar look also in lines anchor inventory having the We neuromodulators. our of With will commercial And DaxibotulinumtoxinA approval portfolio our inspection our the pre-approval therapeutics of approved, not their product, to for true category and facility innovation this the FDA our first in the aesthetics over initiated only Revance lay the launch DaxibotulinumtoxinA plans continue introducing XX once for we injection the the years. innovative neuromodulator treatment forward foundation franchise. and

cover the be particularly We the will expect catalysts to the of in business to second With anticipate in let performance me second quarter. that, later turn exciting, I'll our aesthetics call. we of half very and the our Dustin, in several year the this which cover who pipeline, busy over Dustin? therapeutic call

Dustin Sjuts

Mark. you, Thank

built X,XXX XX a is X,XXX up commercial now and quarter. arctic track across the solid using collection or first execution our carrying We accounts with from since accounts initial record have over payment launch of our states, platform. This in

proceeds results consistent continue in confidence our to go-to-market our Our strategy. reinforce

in the sales quarter, RHA million of to $XX by prior the from up quarter. a was education, seasonally During million, Growth efforts for increased complemented sales busy aesthetic our and a also second through period combination procedures. $XX.X injector

noted active procedures and QX more aesthetic compared we've generally and to for are As quarters QX. before, QX QX

for ramped DaxibotulinumtoxinA injection revenue particularly our team patterns, approved. growth of training for fourth launch potential quarter. Given sales our their moderated to expect to up a these the we expect seasonally We QX, once then prepare be in as stronger commercial return to to

a end on $XXX million see were at in to a becoming service to continued pleased PayFac, controls We're completing big in accomplishment, significant QX. testing, are platform. With growth for extensive we value payment offering unlock positioned substantial target rate, organization, regulations. our and QX as to million platform's We entail in volume of facilitator well fintech practices. now aesthetic processing of the to entire an authorized also over our run launch the up to undertaking Turning the $XXX and the over

to processing PayFac, in we'll participate value our to more enhance a enabled a as As proposition source to value a card build features Further, credit and of chain. PayFac be the offering. overall leverage new the services functionalities reminder, that us data able of

Fintech market, beta-testing in now fourth are We quarter. the to which we in commercially the platform, our launch next-generation expect

details finalizing and on roll to soon. are the We platform plan forward look new more out sharing

the new service Until revenue and both rate. underway, technical we activations accounting will processing and the with we'll and new moderating commercial the account then, when preparations the payment volume platform new the be platform. Given legacy include of our launch for run

like turn the Revance I'd of hires Mark, to call across I commercial support a key recent evolution. therapeutics to aesthetics in introduce and few our Revance Before

Bank, in developing evolve leveraging aesthetic financial First, as organizations, the her products of experience, franchise. share services the in the designing look as Käthe our over and while He our platform. experience commitment to Käthe to excited of at pleased Umpqua appointment ensuring e-commerce as forward of setting and XX part segment, board and of I'm successful leading fintech Citigroup Services and General Manager strategy We're our to to next-generation to aesthetics payments, her our long-term also continue services platform. fintech in and on including years consumer building services grow launch leadership PayPal. have will brings instrumental fintech Anchel our a in we be smooth Financial and of

to now As at critical inflection we're a therapeutics, point.

a III closely behind preparing for the in very are pivoting injection for adult spasticity, limb cervical trial is launch which our II. preparations, for DaxibotulinumtoxinA of dystonia, We to following Phase treatment data of commercial for our clinical focus Phase pivotal strong following successful from

was global Manager bringing has strength of background XX a Bancroft these Therapeutics. team, both company in Rob our for CEO announce to and advance through look Vice our solutions discuss life bladder. will Schilke] QMENTA, franchise diseases. that, strategies Prior With we're space. our Healthpoint our and in [Mark] For upcoming Rob the we call President of to pipeline Toby in The Rob therapeutics for and adds therapeutics, on the sciences franchise industries. is brain also He a toxin outlets. to of groundwork place, General experience than accelerating value With development strengthen Executive to pleased of focused he overactive the the the strong laying migraine, that, and spasticity, of strong help like our record, all reasons, the on expansion Biotherapeutics. forward for strong growing development, therapeutic pipeline therapeutic background team infrastructure the strategy market. [Mark a pipeline over entering was modulate appointment turn the as our our of investments commercialization. more At clinical elevating therapeutics Allergan, the in Toby? instrumental global years for and Rob $X.X Most I'll billion to leading of back healthcare Rob track neurogenic recently,

Toby Schilke

Thanks, Dustin.

therapeutics year. second We of key pipeline the in the milestones are anticipating our half in

in we filing to safety our anticipated dystonia. Dustin approval evaluating study. with for trials the mentioned, Afterwards, plan are expect on In the treatment results ASPEN of clinical the half, Phase currently III we application from open-label XXXX cervical second in in share long-term As biologics DaxibotulinumtoxinA the license we XXXX. supplemental for injection

Our upper adult also limb spasticity. III is for clinical in team preparing Phase program a

study to our our amortization recall in February You'll [Technical DaxibotulinumtoxinA completed stock-based JUNIPER remains compensation. II plan year, for an Phase activities end and II of Phase we Difficulty] include this for and injection. and SG&A hold Commercial expenses the that of depreciation

costs $XX.X expenses related were regulatory Research for SG&A expenses million. biologics and were and our application, non-GAAP compensation. Excluding for pre-commercial clinical these R&D to manufacturing and amortization expenses, depreciation trials, stock-based million $XX.X development quarter, expenses development. include second support platform reflecting ongoing and fintech license the

expenses Excluding million. these R&D were expenses, non-GAAP $XX.X

operating continue second believe XX.X remains Cash, plan diluted over the million of the the investments financial balance Difficulty] we XX, XXXX. which XX.X with We And to into equivalents excluding $XXX.X reaffirmed fully [Technical approximately sheet announced shares, is previously XXXX, to convertible and Mark. Further, of half million year. short-term the turn fund balance sufficient I'll that, we into for call our with XXXX discipline our with strong guidance. debt. cash were our and impact to back of the as June million, heading growth quarter, during

Mark Foley

we're a strong proud anticipate Thank year of you, for second finish performance injection in In our closing, Tobin. in of with in and the very the and advancement the our half of the pipeline. half DaxibotulinumtoxinA first therapeutics further approval potential

growth with cash call division a also our I support that, into questions. to open remain the will We XXXX. initiatives Operator? now up With financial for solid position in

Operator

Fernandez first Thank you. question from the Instructions] Guggenheim. have will line from our We of Seamus [Operator

open. Your line now is

Seamus Fernandez

much. very Thanks

question. follow-up. do I'll just and my So with first But kick-off question to the one

they I'll And pent to Would relative second thoughts the commented second I - to about taking then third under really market Congrats just it very that one then quarter. follow-up the that One just quarter. was - the they thirds share one statement? was of have regular comment you thing really your what growth on up. AbbVie Your think that of on moniker, two was way as and very, guys approximately around means And your sort anticipated a maybe about it? guys' question. demand delivered that the demand strong Allergan of on other you relative

Mark Foley

phase. of better got data I don't Mark. Seamus, launch than any that. this is we've in know We're sort that

there's accounts we're with dealing focus fraction a nature say of backlog. market. I our sort the and that the that high-end these smaller accounts, would Having represents pretty obviously, the prestige that, said So healthy of overall of a definitely on

very that our in you accounts, X,XXX tell and were between now. services I anything additional roughly them. feel good expect We pent-up that everything no least overall in now to entering know consumers But to we've returned the somewhat clearly, some for with we so have market are we healthy in certainly, are pre-pandemic. feel that that to add. There's seeing good with with But the We else. where we're we're about we'll There's Zoom we nice products accounts doubt see so some where and right pretty the new back levels market effect the at being And growth. as that would were are can we that clearly or talking targeted. market, very don't market we're that And continue there's demand. a

Seamus Fernandez

on just question quickly the Great. the very launch. expressing confidence of And high then a obviously, you're degree as in just second

inspection just that uptake, encourage give sense us general And could is so through and Maybe about and of going I'm would to launch kind just given Thanks. maybe of the premium versus rollout should rollout quarter the strategy the in think specifically, XXXX? just how we but about through guiding fourth you balance obviously, the balance a think the your of how swimmingly. the you assuming the FDA us without

Mark Foley

Yes. Thanks for asking that.

FDA the inspection process of consistent to our we're on First, the part PAI, we everything PDUFA prior at, been indicated inspection we a addressed that press prior except waiting had commentary, due had our FDA with on-site that and for released been where date, a for to And an where date occur. scheduled delays, that not bit holding to pattern then as of we were in the yet.

to this our our that the at press physically up inspect and and the remarks, of that then given in first drug Given date remote spring, to shown inspection the without they're approval, obviously, possibility facility. QX. occur inspection we've been has in end before And FDA to our release out an in is plant. the a going release press We put our need

to through feel expected following good plan. continue inspection we that So the of very sort with they're

sensing continue commercial our our of and sort We've with to the taken tone time of before approval the expected keep our year-end. preparation to consistency around think inspection readiness this plans. I for advance up you're advantage

trials. be tried our filler In result, consistent. that RHA trajectory, in of first the a used very similar we're thoughtful to to with we've This what terms has time phase we And the been of of be did launch outside clinical the intentional our sort product the going will of and first line. also as to be launch,

to commercial going balance time to XXXX I that think likely consistent get we're for going of most to spend with clinical reproducible our post approval, and good, so is this the And more our phenomenon. year And a that of focusing are that be on outcomes likely launch ensuring we're much trial of really data.

group thinking about there but we post some will need getting to this real spend period before with through launch. of approval, where experience commercial that's how time going we're going to select are a customers, stub be a traditional more So it, low

Operator

Flynn Sachs. Thank you. line next question from Goldman And now comes the of our Terence from

open now is line Your

Terence Flynn

DAXI quarter the a just taking follow-up, then Mark, just here. agency, your for questions. Thanks the a one for X side. XX strong In that's a filler noted time still I the wondering on line to for turnaround from manufacturing if past, week you've Great. think And the Maybe the obviously, side expectation? about

So side -- seeing from just of contributed, the you. Thank obviously, wondering things? what breadth and you're but reorder

Mark Foley

Yes.

frame So it set issues. any give is going It's the where of relates a sort work know PDUFA time frame to we're framework, agency time they're as is best, to of the first the the didn't within that outside inspection. think, trying their of outstanding deadline. exactly off, moving these towards we to intentionally PDUFA to I everything the the under resolve because clock, Clearly, hard

schedule build certainly on pick the to that end continue before and of the we so And in commentary full an on interim. focused and approval XXXX, have our going preparation we're

going another had pull dynamic might to willing otherwise introduce rates, us our may new reorder to of still lot it. This out commentary of us, expect business quarter with full online, to the accounts percent we a third I it's of still of practice. then willing bit coming change of their sort lean a neuromodulator cycle make we And are seeing of it accounts the in which and filler early this fits that little our there to accounts we're also think giving we a a back. that is figuring that the launch in approval for and consider waiting a until little around to Regarding where be that's in

next data you. of bit think So Thank that still reflective bit we we a happy little to we and it's is Operator in early We're certainly more like going forward. share, early to business have think as Thanks, going get as we're little that but the visibility think I process. what a still is question? look

Samimy of Your Stifel. next question Annabel the line from comes from

Your line is now open.

Annabel Samimy

my taking for Thanks Hi. question.

filler doing are you can Just work, commercial bit ahead outside contracting, do? decent of Is a as education You've contracting approval. the more the potential little such penetrated a on potentially negotiation? that happen And you smooth for that process. to training that obviously momentum work, can of preliminary What much on process not you're this any and stuff the there side, the I that that away preparations able accounts. of the of anything commercial Is from could a pull having? the the you're then amount ahead too you said time do and that of preliminary that launch is there of energy manufacturing realize

means about board a it this there you're that would on I as half, Thanks. do that up, come the keeping that so and any be if of -- of of say? Or And to there's telegraphing and you're just a forth, going you're and still issues back you is that? for process any second imagine that's part bit are what

Mark Foley

do or from anything until first we can have not So there's that of promotional commercial prep, a approval. approval, on we in the absence the much obviously, standpoint

refine prep, work about been around that pricing continue - it's when we we've market to more we strategy and research our all talk doing. So commercial

launch of I between approval the think of gap relationships expected customer neuromodulator with this that we've to physicians of build at filler the advantage level. the further taken the and

to the we're for establish aesthetics So prestige brand. continuing Revance

from both product talked towards of of we now advance as I inventory see us building a company broader then obviously, a products, launch. working range a And stage. a and in think that's people services about

the to and internal getting our everything is materials support that. all So launch one of activities, sales preps ready

doing of commercial we're kind the that's more side. of on So what prep

commenting we our about a we talked kind the the then that been to had scheduled in June. were inspection we of release the PDUFA. prior that FDA end been broke side, not had protocol out the when press scheduled given manufacturing where the pandemic fact on for journey, And again, in of On one putting

before needs read piece about is I that into standard sort wouldn't to So This commentary happen a my of process. approval.

the were decision. where process of our get to very we prep come from kind the all our we So product. the us that you'll But hear in hopeful we in back preparations again, the communication we that continue about and approval good and once of fact is of next feel the

question? Next

Operator

Thank you.

line question David comes of from the Piper next from Amsellem Our Sandler.

line is open. Your

David Amsellem

Thanks.

traction question that have on Or know about have field? then X should say, first just about don't relatively can I And expect prepared sort particular are that's have And different the practices you you commercial days. in the there things commercial there more have among given and terms should neuromodulators and, are one. as early are of can your In any there we this fillers. or for, remarks is two, DAXI? out still the that expect training over to life, sorry on missed are far? other you that we talked talk if you number So it, any to us Are it's the remind the there a that in But trained know of months in but words, the evolve, get if many thus just and you in the mix real number of there some So going I I of sales what seeing within once SKUs? injectors predominating? filers. what injectors. DAXI force of early are life than of gained cast you time, these you the affinity how first XX net are of expansion, approval,

about So how we Thanks. think should that?

Mark Foley

David. Thanks, Great.

it Obviously, been major on still limited We're that And hear that on characteristics. shift figuring I've not was on RHA it, we're X. third, field, RHA surprised you'll one didn't lines. we've been early, We're range I seeing on they indications out. the third side people else those one comments of quarter are this X, finding and QX said that a a And to QX. still people places already are out or our the what think performance a it. previously glabellar one I for think between scripted mix different of third, roughly the the using So focusing when that on address somebody was that the performance of from in kind first last we we folks we're use But like characteristics a

separation I'm the some the third, the even. now, it's over to But continues we'll see third, presumably So right it pretty split, be still right sure now, third. time.

we're that our launch before is X to the and to injector what of terms out we that of In the third to the we of that in we XX half are the XX,XXX we've be in accounts about neuromodulator of top third. talked and how would committed that remain the that a about and thinking strategy post in and going over US, roughly we're are months targeted XX,XXX kind launch, targets to those top think after really there are time expect prestige

So now, because RHA to they obviously of no sort leaned our because accounts. be going the with we're to right strategy. bias pricing. of are in after first of go the They like accounts in Those idea X,XXX prestige

of that's customers same we the to the differentiated value are so going that our And expect appreciate group neuromodulator. of

the little kind early expect we about we're to so target accounts that of over still number a time. of to And exactly talk

accounts from that to we're building of that of outcomes. sure sort is the broadly And once is we'll will towards little us. have leaning that are to that, strength position in starts used there no guidance. going then number interest prestige I approved. expressed the neuromodulator with going a introduce of an accounts more it in commercially an I certainly after But a have us to more that be think I Phase as getting that make terms bit in with is there's the be broader a interest then think the of And product that doubt already

David Amsellem

Thanks. Great.

Operator

Thank you.

Blair. the comes from Tim question next of Your from Lugo William line

is open. line Your

Tim Lugo

you revolve launch know over the question see an with heard you're Just and DAXI this? I RHA that most what maybe how all this and often. years, approval us thought But from the the kind excitement just from often, really you that I of refresh of to DAXI, wanted hearing long-duration to they on agree hearing past just of the taking and around hopefully, marketing? want neurotoxin And could but I in who thoughts some ahead around you're with don't have and their on a few used the trials asset from physicians, questions. the versus more for phone interest view. physicians an the patients the field have not of of, clinical of Thanks update short-acting the probably less

Mark Foley

Yes.

clinical seen duration So couple and to that long neuromodulator in of up. Tim, despite practice bring relates of as it a sort times profile X.X might that months, only sort come a clinical four the there market we'll neuromodulators that in year with trials of the data our of lot of fit the we've months, sort and out conventional impact how data points at that three kind of consumers or There's less. lasting average that into

it So think to in pattern of foremost, normal well we is what very first consumers. and the figures

particularly with waiting field, the we've the going these long prestige been Secondly, out anything we're after, have if on that folks lists. when accounts

the getting challenge. into accounts And these so is

well you do way also And filler you your patients more a if that setting. of the with only treatment twice fits were really the year providing so same services services And a the sort well. can a increased as offer neuromodulator increase that at necessarily profitability you're provider, to so you can every

per-visit this of filler So outcomes the both makes patients to increase kind better sense. of give a to add can together ticket idea you that neurotoxins sort and and

creates that and in also are strategy, physician for a to, - everything, we've choice level consumer a bias into thing does last the level. underpins that I it that the the say So us what leaning innovation The lot. would those at resonates talking customers is, prestige but and the choice obviously, create got we're more towards at

to everybody. neuromodulator, longer-acting everything be And not trying to so a with we're

three, number a there and that year, lasts to that a consumers that times they practice a a want a insignificant premium great. of our That's practice consumers think But in prefer research, we not are case that's often. the on market will so longer. based that put really coming neuromodulator more on And four there's in

think lot to of provide And is sense. what so practice we choice, a figuring able being makes out this

feel the to and value consumer good continue and really to about this a we proposition how practices from a fit from going So profitability demand into is both standpoint.

Tim Lugo

That's you not would a category, hear. And great Thank I you're majority I research franchise the the market of In of dystonia, why the clarifying. one - addition - to for indication in follow-up. the side? don't share maybe my the can understand us just capture in therapeutic maybe would an a long-duration could to like be you eventually product cervical talk some Rob. know the side remind market and to research obviously But about therapeutic your adding of therapeutic of with not

Mark Foley

share It Sure, therapeutic actually the sort we that Tim. research shows market say become in of as a that well. -- shows I that's area our what leader. could would

it It's visits less to fact and a system, the symptom the ability the fee, stress also reduce frequency of takes think right? it that I speaks some everything diseases prolonged off of facility are debilitating and physician obviously but gives to time relief, the else. that these

signal CD we well as the strong rates. from really had program, the so data low if generated our not a duration encouraging dysphagia a And with look profile, was at safety but very only that you we

in therapeutics. the And neuromodulator trials so optimistic are performance and really clinical we about

and of in to announced we ready that's the of for new that product why therapeutic about get very And the indications market. of starting the some we profile introduction feel performance dystonia commercial hires the cervical our so have good

Tim Lugo

question. the Thank you for

Mark Foley

Thanks, Tim.

Operator

Thank you.

Balaji question comes of Prasad next the Our from Barclays. from line

our open. Prasad. is Again, from Balaji next of line Your question comes line now the

now line Your open. is

Balaji Prasad

the net how afternoon, asked this back - the go rate of of and has Good but tie Apologies just could try this to opening opened Hi. to been the to to to your launch? Thanks. And everyone. end year? accounts opened want before, DAXI accounts be question. account by this number what's Thanks X,XXX up for this if extrapolate likely the eventual the to as run quarter

Mark Foley

Yes.

We've platform the of a each combined which line product RHA and services our total lot. thanks of So number end at products, between sort of our reported quarter. is accounts the our

there at end about now of the being the of end over end at of talked X,XXX at QX, and at end XXX QX, over QX, we of the So QX. over the over X,XXX X,XXX

XXX some So been of activation averaging existing out, going deeper new as say, new sort But with we think with products accounts to per so and these have we is we're some in Obviously, need new look or that making sure we've and to that quarter. the account the that coming services programs of now. are accounts. the for important I numbers those reasonable of

certainly these have the continue accounts our the not right tracking of to be as I view could target But that we to sort approval new for in XXX of we'll balance of to market unreasonable account year. of this it's something opportunity. because, adds post room is per think to neuromodulator, at that quarter, need now, look our with exist . run clearly that We a strategy lot revisit again, our much more

Balaji Prasad

helpful. this are Thanks, you that bias a post one just rate of maybe to Mark, your months on the in a data is And that's see quick the package BOTOX FDA ago? submitted where with submission? couple to Sorry, regard

Mark Foley

that next for determine was III that biosimilar, in required be On a what that to program agency to meeting with the Phase we would the approval. program the have step the indicated is

on their end. the will that we more happen there them. I soon, look before has be before of again, with like year we've the agency that lay We bit the encouraged to out call with little but agency continue it, year-end. sort coming to by And that to dialogue going is had program know that a be meeting own what up they conference expect might commentary a give to

Balaji Prasad

Mark. it. Got Thanks,

Mark Foley

Thanks.

Operator

Thank you.

Our next line Company. Belanger from question Serge of & the comes from Needham

Your line is now open.

Serge Belanger

Hey, good my taking questions. afternoon. for Thanks

second cervical be First which If are half. one treatment. in for of refresher study safety courses multiple a patients give in you the us open-label from of reporting you'll dystonia, to Can recall, eligible the just Mark. receive I results

what an So terms and duration give in maybe be us looking safety? of you'll efficacy, just for idea of

Mark Foley

Yes.

open-label really at escalation a endpoint of looking over study, dose sort the at repeat the on doses So of study, that safety it safety primary to was look time. was

report out, how of the and in we these over and the decide. a patients time at when what doses so that safety again, looking if that product occur respond more profile clinicians doses it's the much of an ultimately different to, increase that's And

safety about about less sort side duration it's of it. So of the the and profile more

we'll be reporting on out that's So what that.

Serge Belanger

with secondly, Rob confirmation commercialization that team, the commercial partnership? kind view that addition muscle movement of to at look forward with of we in the the of you're for moving as Bancroft And the therapeutics effort disorder should Okay.

Mark Foley

correct. that's Yes,

to so last of senior addition person the as reimbursement Rob, level another announced addition side on well. we that that healthcare that focusing also -- quarter the In we're on

sales we've putting allow And key in our about that in to building space. of and force to talked pieces so the that focus out the access place we're of market. on some direct long a these sort us are movement enter muscle And

and filing it cervical dystonia, approval to relates in As we about in 'XX 'XX. talked

opportunity profile us away. And far talked competitive we in to there. performance bit allow very as product the therapeutic So think we be previously, there's And fair a our not the of we too unlocked that believe it's be category. will of to that

Serge Belanger

Okay.

Operator

line of comes Cowen. from question the from Ken Cacciatore next Our

open. line Your is now

Ken Cacciatore

really performance great having you without yet team? Congratulations, are just DAXI. doing, How

so at marketplace maybe there much. that Can you key the different of as to be the really you the know, forward, Mark, give in Is the going of of been we how XXXX, thoughtful of near think try not users this product future? this experience has differentiating timing BOTOX want the think and all can experience, or of have. out maybe terms us some overall AbbVie that for we anything DTC rolled - nuances back a little step maybe any of kind initial terms the So bit apply the you to past in the you franchise. Kind in doing different different could you talk Thanks and has the bit they're part necessarily control the in that approach kind product now taken as over little as latter term. do of look we're a as market you through to that you about all I that and has of

Mark Foley

Thanks, the a I they mean, push lot Ken. talk big injectors. DTC market They've No, about as a of leader, sort dollars. really. increasing obviously, training new not into got

of So the actually of folks number are to doing toxin sort they're expand treatments. going that

things top in a little Our concert, on overall it. going the side different, to strategy of think sort these of all are that doubt of the going after no market. We're grow I is But help of happening the pyramid right?

practices. to the they're will if So training help of come grow but which we more dollars, to playbook, couponing innovation, on we awareness will more to in, focused much we is of of coming is as more into their the prestige high-end market. also drive which would are expect And customers, that going going injectors, these to run and awareness market ours continue kind with new consumer who all again be more

we So we'll view that don't the overall quite will whole any once playbooks Certainly, hit But from in standpoint. approach that expect of hit both kind differences the once the that to have from we there. be different going us a lot the sure I'm competitive. market, way we we market. But terms of of the see an run it's don't market, I major to

Ken Cacciatore

so Thanks much.

Mark Foley

Instructions] Mizuho. of Our the Thanks. next Operator question Vamil Thank comes line from you. from [Operator Divan

open now is line Your

Vamil Divan

the taking question. for Thanks Great.

market you would a One side So as for you maybe your if a that the you being a matter work of provide that, new anything when of you evolving the to on obviously pretty migraine but that couple kind have insight quarter. on you for part, me. efforts any just about might maybe provide you curious update is around more sort going there's Can do then business? benefits just And your and that PayFac second talked that think as just little to of if that's next about rapidly of opposed integration well. you've maybe for talked on the be around as work that just

thoughts helpful. Thanks. So any new be would

Mark Foley

Thanks, Great. Vamil.

- data. PayFac the the stream big addition the margin level advantage is the more of PayFac it to of source access to advantage gives participating processing credit the first on So real card side the overall is in of in it, us to

HintMD level access system now, source but the give credit right robust it necessarily us data. a is the processor, card So doesn't to

source if analytics things up set don't and data. data a around loyalty a in you the to So insights automating white label to and becomes subscription services easy even have access seamless lot way that's and harder and

a So data use then be turn able with then around can that facilitator, and to them by we scrape information, and it data, again, that which, will help practices the analytics. becoming we are source to payment insights but

And going -- piece really so the that's to that's functionality hand. key functional

of will on encouraged and So how to And these the with again, margin And services again, on us we're choose going will more launch ability to that that be spread if performing. we of. of a build choose sort them data to the participate the will other allow top it's to is little foundation to how back if that bit it very in hold we practices. the give that or out

is the your planning and part I that said it, we we if most not On sort as recently it, cycle. this of sort migraine of an think to of XXXX of our what we And side talked point, would consider when. about

our little have on that And so to to give when we operating where strategy we'll more priorities fit for and plan. XXXX think, prepared migraine therapeutic our we I XXXX what be, better a sort in bit address overall of ultimately color

Vamil Divan

right. All Thank Okay. you.

Mark Foley

Thanks, Vamil. Operator you. Thank

from Our next Wainright. H. of the C. Douglas question comes Tsao line from

open. now is line Your

Chris Bialas

quarter. Douglas Congrats the Bialas here Chris on for on everyone. Tsao. Hi,

now. just prestige a DAXI So for bit in that I little you're the segment interested was targeting

Thanks, millennial was is competitor between much targeting demographic. segments. these two just wondering Our And that yours heavily I is the overlap how

Dustin Sjuts

Chris, is this Dustin.

I think we practices. separation need consumer to segmentation in and separate the around around

prestige provide as patients. focus outcome drive on our with as really to partnering experience is those an they the is practices rise value around, to patients So well that they strategy to the

all Those see all types. practices patient those So between. might be that millennials and ways

us strategy we with from our and the loyalty that the products innovated they providing than we build amount the that experience most then really treat believe the consumers and practices loyalty to practice. So different of those great is other that by directly can

our those So to driving loyalty in lies it really factors.

millennials those as will that much So coming into factors space, see the be others. just the as will the all

Chris Bialas

helpful. Perfect Thank and awesome. That’s you. very

Dustin Sjuts

Thanks, Chris.

Operator

[Operator hand you. to Instructions] Thank now I like back We Mark don't to have call the questions. Foley. any further would

Mark Foley

Thank you, operator.

our quality My I the understanding milestones Before that was is the section recap for second of I some my great. to sound make closing just not for half. that comments, wanted therapeutic

on license the in share second study. we year, So the our of biologics second we plan in cervical results application spasticity. of Afterwards, And expect half, then this again, our in for a limb team supplemental - XXXX adult XXXX. we And program. clinical preparing filing to long-term half with also is expect safety in open-label III a anticipated ASPEN dystonia upper for our that's Phase program

FDA year, completed You'll February Phase recall JUNIPER in end remains that before our with Phase year-end. study II and the hold of an II we plan of this to our meeting

are some time. reach we welcome of that, if all through request coming and out things Wells for Feel in thank us. participating With plan attend healthcare We Jessica These your directly free to conferences. to the events call. to out you'd you schedule meetings. Citi like So to to months, in close for the today's to like I'd virtually Fargo Thanks.

Operator

this you for gentlemen, Thank today's Ladies call. participating. conference and concludes

disconnect. now may You

Revance Therapeutics (RVNC) 8 Aug 212021 Q2 Earnings call transcript